Related Experiment Video
Updated: Feb 27, 2026
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
Abstract:
A partnership between the FDA and the American Society of Clinical Oncology's CancerLinQ provides regulators with timely, real-world data on newly approved cancer therapies. The alliance may help investigators gain insights and assess the impact of drugs in patient populations that are not well represented in traditional clinical trials.
Insights
The U.S. Food and Drug Administration (FDA) partnered with CancerLinQ to access real-world data on new cancer drugs. This collaboration aids in understanding drug effectiveness in diverse patient groups beyond traditional clinical trials.
Area of Science:
- Oncology
- Regulatory Science
- Health Informatics
Background:
- Traditional clinical trials often lack diverse patient populations.
- Real-world data (RWD) offers insights into treatment effectiveness in broader populations.
- The U.S. Food and Drug Administration (FDA) requires timely data for drug approval and monitoring.
Purpose of the Study:
- To describe a partnership between the FDA and CancerLinQ.
- To highlight the use of real-world data for evaluating newly approved cancer therapies.
- To explore the potential of this alliance in assessing drug impact on underrepresented patient groups.
Main Methods:
- Establishment of a data-sharing partnership between the FDA and the American Society of Clinical Oncology's CancerLinQ platform.
- Leveraging CancerLinQ's extensive real-world patient dataset.
- Analysis of anonymized data for regulatory decision-making and post-market surveillance.
Main Results:
- The partnership facilitates access to timely, real-world data on novel cancer treatments.
- Regulators can gain insights into drug performance in diverse patient cohorts.
- Potential to identify treatment patterns and outcomes in populations not typically included in clinical trials.
Conclusions:
- The FDA-CancerLinQ alliance enhances regulatory capacity for evaluating cancer therapies.
- Real-world data is crucial for understanding the broad impact of oncology drugs.
- This collaboration supports more informed decision-making regarding cancer drug approvals and patient care.
